

Case number	Use in paper	Age	Gender	Bev-Resistant	Bev Treatment	# weeks Bev Treatment	Molecular Subtype	Recurrence #	Treatment History
SF7796	PDX	56	M	Yes	Monotherapy	18	Mesenchymal	Second	TMZ+XRT -> Recur -> Bev -> Recur
SF8106	PDX	63	M	Yes	Monotherapy	8	Mesenchymal	Second	TMZ+XRT -> Recur -> Bev -> Recur
SF8244	PDX	58	M	No	Not applicable	Not applicable	Proneural	First	XRT+TMZ->Recur
GBM43	PDX	Not available	Not available	No	Not applicable	Not applicable	Proneural	Not applicable	Not applicable
1	Archived Microarray Data	45	F	Yes	Bev+CPT-11	8	Proneural	Second	TMZ+XRT -> Recur -> Bev+CPT-11 -> Recur
2	Archived Microarray Data	48	M	Yes	Bev+CPT-11	11	Mesenchymal	Second	TMZ+XRT -> Recur -> Bev+CPT-11 -> Recur
3	Archived Microarray Data	59	M	Yes	Bev+CPT-11	16	Proliferative	Second	TMZ+XRT -> Recur -> Bev+CPT-11 -> Recur
4	Archived Microarray Data	62	F	Yes	Bev+CPT-11	36	Proneural	Third	TMZ+XRT -> Recur -> CCNU -> Recur->Bev+CPT-11->Recur
5	Archived Microarray Data	61	M	Yes	Monotherapy	14	Proneural	Third	TMZ+XRT -> Recur -> CCNU -> Recur->Bev->Recur
6	Archived Microarray Data	36	F	Yes	Bev+TMZ	16	Mesenchymal	Second	TMZ+XRT -> Recur -> Bev+TMZ -> Recur
7	Archived Microarray Data	58	M	Yes	Bev+CPT-11	51	Mesenchymal	Second	TMZ+XRT -> Recur -> Bev+CPT-11 -> Recur
8	Archived Microarray Data	52	F	Yes	Monotherapy	35	Mesenchymal	Third	TMZ+XRT -> Recur -> CCNU -> Recur->Bev->Recur
9	Archived Microarray Data	63	M	Yes	Bev+CPT-11	4	Mesenchymal	Third	TMZ+XRT -> Recur -> CCNU -> Recur->Bev+CPT-11->Recur
10	Archived Microarray Data	50	F	Yes	Bev+Carboplatin	8	Mesenchymal	Second	TMZ+XRT -> Recur -> Bev+Carboplatin -> Recur
11	Archived Microarray Data	56	M	Yes	Monotherapy	18	Mesenchymal	Second	TMZ+XRT -> Recur -> Bev -> Recur
12	Archived Microarray Data	52	F	Yes	Bev+CPT-11	13	Proneural	Second	TMZ+XRT -> Recur -> Bev+CPT-11 -> Recur
13	Archived Microarray Data	40	M	Yes	Bev+CPT-11	28	Mixed	Second	TMZ+XRT -> Recur -> Bev+CPT-11 -> Recur
14	Archived Microarray Data	49	M	Yes	Monotherapy	18	Mixed	Third	TMZ+XRT -> Recur -> CCNU -> Recur->Bev->Recur
15	Archived Microarray Data	61	M	Yes	Monotherapy	7	Mixed	Third	TMZ+XRT -> Recur -> CCNU -> Recur->Bev->Recur
16	Healthy Control for blood ELISA	24	M	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
17	Healthy Control for blood ELISA	30	M	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
18	Healthy Control for blood ELISA	28	F	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
19	Bev-naïve recurrent GBM for blood ELISA	63	M	No	Not applicable	Not applicable	Mixed	First	XRT+TMZ->Recur
20	Bev-naïve recurrent GBM for blood ELISA	71	F	No	Not applicable	Not applicable	Proneural	First	XRT+TMZ->Recur
21	Bev-naïve recurrent GBM for blood ELISA	57	F	No	Not applicable	Not applicable	Mixed	First	XRT+TMZ->Recur
22	Bev-naïve recurrent GBM for blood ELISA	37	M	No	Not applicable	Not applicable	Mixed	First	XRT+TMZ->Recur
23	Bev-naïve recurrent GBM for blood ELISA	52	F	No	Not applicable	Not applicable	Mesenchymal	First	XRT+TMZ->Recur
24	Bev-naïve recurrent GBM for blood ELISA	48	M	No	Not applicable	Not applicable	Proneural	First	XRT+TMZ->Recur
25	Bev-naïve recurrent GBM for blood ELISA	63	F	No	Not applicable	Not applicable	Mixed	Second	XRT+TMZ->Recur-> CCNU->Recur
26	Bev-naïve recurrent GBM for blood ELISA	55	M	No	Not applicable	Not applicable	Mixed	Second	XRT+TMZ->Recur->CCNU->Recur
27	Bev-naïve recurrent GBM for blood ELISA	30	F	No	Not applicable	Not applicable	Not available	Second	XRT+TMZ->Recur->pembro->Recur
28	Bev-naïve recurrent GBM for blood ELISA	74	F	No	Not applicable	Not applicable	Not available	Second	XRT+TMZ->Recur->nivo->Recur
29	Bev-naïve recurrent GBM for blood ELISA	51	M	No	Not applicable	Not applicable	Not available	Second	XRT+TMZ->Recur->DCVax->Recur
30	Bev-resistant GBM for blood ELISA	40	M	Yes	Bev+CPT-11	28	Mixed	Second	XRT+TMZ->Recur->Bev+CPT-11->Recur
31	Bev-resistant GBM for blood ELISA	56	M	Yes	Monotherapy	18	Mesenchymal	Second	XRT+TMZ->Recur->Bev->Recur
32	Bev-resistant GBM for blood ELISA	50	F	Yes	with TMZ, then with CCNU	60	Mesenchymal	Second	XRT+TMZ->Recur->Bev+TMZ then Bev+CCNU->Recur
33	Bev-resistant GBM for blood ELISA	61	M	Yes	Monotherapy	6	Not available	Second	XRT+TMZ->Recur->Bev->Recur
34	Bev-resistant GBM for blood ELISA	47	M	Yes	Monotherapy	10	Not available	Second	XRT+TMZ->Recur->Bev->Recur
35	Bev-resistant GBM for blood ELISA	53	F	Yes	Monotherapy	12	Mesenchymal	Second	XRT+TMZ->Recur->Bev->Recur
36	Bev-resistant GBM for blood ELISA	54	F	Yes	Monotherapy	20	Mixed	Second	XRT+TMZ->Recur->Bev->Recur
37	Bev-resistant GBM for blood ELISA	55	M	Yes	Bev+TMZ+Tarceva	26	Mixed	Second	XRT+TMZ->Recur->Bev+TMZ+Tarceva->Recur

Supplementary Table S1. Clinical information on cases used in this manuscript. Shown is clinical information for GBM patients whose tumors gave rise to the four PDX models used in this paper, GBM patients whose tumors gave rise to archived microarray data, healthy volunteers whose blood was used for ELISA, and GBM patients whose blood was used for ELISA. Abbreviations used: PDX=patient-derived xenograft, Bev=bevacizumab, TMZ=temozolomide, XRT=radiation therapy